Group items tagged

High-dose vitamin D3 supplementation in a cohort of breastfeeding mothers and their infants: a 6-month follow-up pilot study. Wagner CL, Hulsey TC, Fanning D, Ebeling M, Hollis BW. Breastfeed Med. 2006 Summer;1(2):59-70. PMID: 17661565 doi:10.1089/bfm.2006.1.59. Objective: To examine the effect of high-dose maternal vitamin D3 (vitD) supplementation on the nutritional vitD status of breastfeeding (BF) women and their infants compared with maternal and infant controls receiving 400 and 300 IU vitD/day, respectively. Design: Fully lactating women (n = 19) were enrolled at 1-month postpartum into a randomized- control pilot trial. Each mother received one of two treatments for a 6-month study period: 0 or 6000 IU vitD3 plus a prenatal vitamin containing 400 IU vitD3. The infants of mothers assigned to the control group received 300 IU vitD3/day; those infants of mothers in the high-dose group received 0 IU (placebo). Maternal serum and milk vitD and 25(OH)D were measured at baseline then monthly; infant serum vitD and 25(OH)D were measured at baseline, and months 4 and 7. Urinary calcium/creatinine ratios were measured monthly in both mothers and infants. Dietary and BF history and outdoor activity questionnaires were completed at each visit. Changes in skin pigmentation were measured by spectrophotometry. Data were analyzed using chi-square, t-test, and analysis of variance (ANOVA) on an intent-to-treat basis. Conclusion: With limited sun exposure, an intake of 400 IU/day vitamin D3 did not sustain circulating maternal 25(OH)D levels, and thus, supplied only extremely limited amounts of vitamin D to the nursing infant via breast milk. Infant levels achieved exclusively through maternal supplementation were equivalent to levels in infants who received oral vitamin D supplementation. Thus, a maternal intake of 6400 IU/day vitamin D elevated circulating 25(OH)D in both mother and nursing infant.

A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. P R Health Sci J. 2005 Dec;24(4):269-76. PMID: 16570523

Demark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, Walther PJ, Gannon M, Vollmer RT. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects o

Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Nutr Cancer. 2005;51(1):32-6. PMID: 15749627

Vitamin D and depressive symptoms in women during the winter: a pilot study. Shipowick CD, Moore CB, Corbett C, Bindler R. Appl Nurs Res. 2009 Aug;22(3):221-5. PMID: 19616172 doi:10.1016/j.apnr.2007.08.001 ESULTS: Vitamin D supplementation was associated not only with an increase in the serum D levels by an average of 27 ng/ml but also with a decline in the BDI-II scores of an average of 10 points. DISCUSSION: This study suggests that supplemental vitamin D3 reduces depressive symptoms.

Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.Nutr Cancer. 2005;51(1):32-6.PMID: 15749627 [PubMed - indexed for MEDLINE]

CONCLUSIONS: Supplementation with n-3 PUFA improves biochemical, ultrasonographic and haemodynamic features of liver steatosis. Our study supports the efficacy of n-3 PUFA as a new therapeutic approach in the treatment of NAFLD. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1143-51. PMID: 16611275 DOI: 10.1111/j.1365-2036.2006.02885.x

Short-term fish oil supplementation improved innate immunity, but increased ex vivo oxidation of LDL in man--a pilot study. Turini ME, Crozier GL, Donnet-Hughes A, Richelle MA. Eur J Nutr. 2001 Apr;40(2):56-65. PMID: 11518200 DOI: 10.1007/s003940170016

Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. onsson T, Granfeldt Y, Ahren B, Branell UC, Palsson G, Hansson A, Soderstrom M, Lindeberg S. Cardiovasc Diabetol. 2009 Jul 16;8(1):35. [Epub ahead of print] PMID: 19604407 doi:10.1186/1475-2840-8-35

Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features.\nDemark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, Walther PJ, Gannon M, Vollmer RT.\nUrology. 2001 Jul;58(1):47-52.\nPMID: 11445478 \ndoi:10.1016/S0090-4295(01)01014-7  

Efficacy of berberine in patients with type 2 diabetes mellitus. Yin J, Xing H, Ye J. Metabolism. 2008 May;57(5):712-7. PMID: 18442638 doi: 10.1016/j.metabol.2008.01.013. Fasting plasma insulin and homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively. Total cholesterol and low-density lipoprotein cholesterol were decreased significantly as well. During the trial, 20 (34.5%) patients experienced transient gastrointestinal adverse effects. Functional liver or kidney damages were not observed for all patients. In conclusion, this pilot study indicates that berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism In summary, that berberine is a potent oral hypoglycemic agent with modest effect on lipid metabolism. It is safe and the cost of treatment by berberine is very low. It may serve as a new drug candidate in the treatment of type 2 diabetes. However, this is a pilot study. The efficacy of berberine needs to be tested in a much larger population and characterized as a function of the known duration of the diabetes. Further studies are needed to evaluate the action of berberine on type 2 diabetes in other ethnic groups.

In a pilot test, the program helped children reduce body mass index, achieve more muscle mass, improve their health-related quality of life, reduce screen time, and increase levels of physical activity.

Phosphatidylserine (abbreviated Ptd-L-Ser, or PS) is a phospholipid component, usually kept on the inner-leaflet, the cytosolic side, of cell membranes by an enzyme called flippase. When a cell undergoes apoptotic cell death phosphatidylserine is no longer restricted to the cytosolic part of the membrane, but becomes exposed on the surface of the cell. First pilot studies indicate that PS supplementation might be beneficial for children with attention-deficit hyperactivity disorder PS can be found in meat fish, but is most abundant in the brain and in innards such as liver and kidney. Only small amounts of PS can be found in dairy products or in vegetables, with the exception of white beans.

"Don't Let This Limited Time Offer Pass You By!" You'll get everything you need to quickly build a profitable MediBank business. Work From Home! Our program is so simple that you can work from home, your office or from any place you happen to be. Due to the magic of the internet, it does not matter where you are. Work On Your Own Schedule! Because of the many creative marketing tools we give you, you can work on your own schedule, day or night. In fact, these tools allow you to work while you sleep or do other things. Part-Time or Full-Time! You can start part-time and build into a full-time business. Invest as much or little time as you desire. In fact, much of your marketing can be passive and on auto-pilot. Total Automation! No inventory to buy or store. No paperwork to complete. No meetings to attend. Everything is totally automated through your website and email. Affiliate Commissions! Earn up to 40% commission on each Affiliate package you sell.

The Toronto group gave a fixed low dose (2,000 units) of the prehormone, cholecalciferol, a very safe compound that never causes high calcium in the doses used. In fact, the lowest dose of cholecalciferol known to cause high blood calcium is more than 20,000 units. Therefore, the Toronto group got better results with one-tenth the comparable dose of deltanoids! Vieth wanted to use more cholecalciferol but widespread ignorance about the physiology and pharmacology of vitamin D remains and he could not get adequate dosing past the various review committees.

Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Su KP, Huang SY, Chiu CC, Shen WW. Eur Neuropsychopharmacol. 2003 Aug;13(4):267-71. Erratum in: Eur Neuropsychopharmacol. 2004 Mar;14(2):173. PMID: 12888186 From the preliminary findings in this study, omega-3 PUFAs could improve the short-term course of illness and were well tolerated in patients in major depressive disorder.